Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Launched by MYLAN INC. · Mar 24, 2017
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is a male or female subject 40 years of age or older with a diagnosis of COPD.
- • Subject has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years.
- • Subject is willing and able to provide signed and dated written informed consent to participate prior to initiation of any study related procedures.
- Exclusion Criteria:
- • Subject has a concurrent disease or condition that, in the opinion of the investigator, would interfere with continued study participation or confound the evaluation of safety and tolerability of the study drug.
- • Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics.
- • Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention.
About Mylan Inc.
Mylan Inc., a global healthcare company, specializes in the development, manufacturing, and commercialization of generic and specialty pharmaceuticals. With a commitment to improving patient access to high-quality medications, Mylan leverages its extensive portfolio and innovative solutions to address diverse healthcare needs across various therapeutic areas. The company's rigorous clinical trial initiatives underscore its dedication to advancing medical science and ensuring the efficacy and safety of its products. Mylan's focus on research and development, combined with strategic partnerships, positions it as a leader in the pharmaceutical industry, striving to enhance health outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rock Hill, South Carolina, United States
Patients applied
Trial Officials
Medical Monitor
Study Director
Theravance Biopharma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials